2. Academic Validation
  3. Blood culture-free ultra-rapid antimicrobial susceptibility testing

Blood culture-free ultra-rapid antimicrobial susceptibility testing

  • Nature. 2024 Aug;632(8026):893-902. doi: 10.1038/s41586-024-07725-1.
Tae Hyun Kim # 1 2,  Junwon Kang # 3 4,  Haewook Jang # 3,  Hyelyn Joo 3,  Gi Yoon Lee 2,  Hamin Kim 3,  Untack Cho 5,  Hyeeun Bang 5,  Jisung Jang 5,  Sangkwon Han 5,  Dong Young Kim 5,  Chan Mi Lee 6,  Chang Kyung Kang 6,  Pyoeng Gyun Choe 6,  Nam Joong Kim 6,  Myoung-Don Oh 6,  Taek Soo Kim 7,  Inho Kim 8,  Wan Beom Park 9,  Sunghoon Kwon 10 11 12 13 14
Affiliations

Affiliations

  • 1 Bio-MAX Institute, Seoul National University, Seoul, Korea.
  • 2 Department of Electrical and Computer Engineering, Seoul National University, Seoul, Korea.
  • 3 Interdisciplinary Program in Bioengineering, Seoul National University, Seoul, Korea.
  • 4 Integrated Major in Innovative Medical Science, Seoul National University, Seoul, Korea.
  • 5 QuantaMatrix Inc., Seoul, Korea.
  • 6 Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
  • 7 Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Korea.
  • 8 Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. ihkimmd@snu.ac.kr.
  • 9 Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. wbpark1@snu.ac.kr.
  • 10 Bio-MAX Institute, Seoul National University, Seoul, Korea. skwon@snu.ac.kr.
  • 11 Department of Electrical and Computer Engineering, Seoul National University, Seoul, Korea. skwon@snu.ac.kr.
  • 12 Interdisciplinary Program in Bioengineering, Seoul National University, Seoul, Korea. skwon@snu.ac.kr.
  • 13 QuantaMatrix Inc., Seoul, Korea. skwon@snu.ac.kr.
  • 14 Inter-University Semiconductor Research Center, Seoul National University, Seoul, Korea. skwon@snu.ac.kr.
  • # Contributed equally.
PMID: 39048820 DOI: 10.1038/s41586-024-07725-1
Abstract

Treatment assessment and patient outcome for sepsis depend predominantly on the timely administration of appropriate Antibiotics1-3. However, the clinical protocols used to stratify and select patient-specific optimal therapy are extremely slow4. In particular, the major hurdle in performing rapid antimicrobial susceptibility testing (AST) remains in the lengthy blood culture procedure, which has long been considered unavoidable due to the limited number of pathogens present in the patient's blood. Here we describe an ultra-rapid AST method that bypasses the need for traditional blood culture, thereby demonstrating potential to reduce the turnaround time of reporting drug susceptibility profiles by more than 40-60 h compared with hospital AST workflows. Introducing a synthetic beta-2-glycoprotein I peptide, a broad range of microbial pathogens are selectively recovered from whole blood, subjected to species identification or instantly proliferated and phenotypically evaluated for various drug conditions using a low-inoculum AST chip. The platform was clinically evaluated by the enrolment of 190 hospitalized patients suspected of having Infection, achieving 100% match in species identification. Among the eight positive cases, six clinical isolates were retrospectively tested for AST showing an overall categorical agreement of 94.90% with an average theoretical turnaround time of 13 ± 2.53 h starting from initial blood processing.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z